miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway

Figure 3

LATS2 is a target gene of miR-25 [21]. (a) The predicted binding site of miR-25 in the 3UTR of LATS2 from miRBase. The mutated LATS2 3UTR-binding site is indicated. (b) LATS2 expression in 15 pairs of NSCLC tissues and adjacent normal tissues by qRT-PCR. (c) LATS2 expression in NSCLC cell lines and the noncancerous lung epithelial cell line BEAS-2B. (d) Kaplan-Meier curve for overall survival in lung cancer patients with high or low LATS2 expression. Data were taken from TCGA. (e, f) Luciferase reporter assays in HEK-293 cells. (g, h) Luciferase reporter assays in H1299 cells. HEK-293T, A549, and H1299 cells were cotransfected with pRL-TK carrying a wild-type or mutant 3UTR of LATS2 and the miR-25 precursor (60 ng) or the miR-25 inhibitor (10 pmol), and the luciferase activity was measured 48 h posttransfection. (i) Western blot assays for LATS2 in A549, H1299, and BEAS-2B cells. (j) Western blot analysis of LATS2 in A549 and H1299 cells transfected with miR-25 precursor or the miR-25 inhibitor. Experiments in this section were performed using our documented protocols [21]. Results were presented as the . and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)